Phosphorylation of TGIF2 represents a therapeutic target that drives EMT and metastasis of lung adenocarcinoma
BMC Cancer volume 23, Article number: 52 (2023)
TGF-β-induced factor homeobox 2 (TGIF2) is a transcription regulator that is phosphorylated by EGFR/ERK signaling. However, the functions of phosphorylated (p)-TGIF2 in cancer are largely unknown. Here, we investigated the roles of p-TGIF2 in promoting epithelial–mesenchymal transition (EMT) and metastasis in lung adenocarcinoma (LUAD).
In vitro and in vivo experiments were conducted to investigate the role of TGIF2 in LUAD EMT and metastasis. Dual-luciferase reporter and ChIP assays were employed to observe the direct transcriptional regulation of E-cadherin by TGIF2 and HDAC1. Co-immunoprecipitation was performed to identify the interaction between TGIF2 and HDAC1.
Downregulating the expression of TGIF2 inhibited LUAD cell migration, EMT and metastasis in vitro and in vivo. Phosphorylation of TGIF2 by EGFR/ERK signaling was required for TGIF2-promoted LUAD EMT and metastasis since phosphorylation-deficient TGIF2 mutant lost these functions. Phosphorylation of TGIF2 was necessary to recruit HDAC1 to the E-cadherin promoter sequence and subsequently suppress E-cadherin transcription. Meanwhile, inhibition of HDAC1 repressed the TGIF2 phosphorylation-induced migration and EMT of LUAD cells. In xenograft mouse models, both inhibition of ERK and HDAC1 could significantly inhibited TGIF2-enhanced metastasis. Furthermore, TGIF2-positive staining was significantly correlated with E-cadherin-negative staining in human lung cancer specimens.
Our study reveals the novel function of p-TGIF2 in promoting EMT and metastasis in LUAD; p-TGIF2 could be a potential therapeutic target to inhibit LUAD metastasis.
Lung cancer is the leading cause of cancer-related mortality worldwide with a 5-year survival rate of less than 15% [1, 2]. Lung adenocarcinoma (LUAD) accounts for ~ 40% of all lung cancer cases and is the most frequently diagnosed subtype . Despite improvements in our understanding of the pathogenesis of LUAD and therapeutic advances , tumor metastasis still represents a serious threat to patient survival.
Epithelial–mesenchymal transition (EMT) plays a key role in tumor development from initiation to metastasis [5, 6]. EMT is also associated with multiple other molecular processes, including tumor immune evasion . During EMT, cancer cells lose their cell-to-cell contact by inhibiting epithelial (E)-cadherin expression and upregulating genes associated with the mesenchymal-cell phenotype, including those encoding N‑cadherin, fibronectin, and vimentin . Consequently, loss of E‑cadherin expression has been associated with metastasis and poor prognosis . Continuous EGF treatment has been shown to downregulate E-cadherin expression and result in the loss of cell–cell adherence junctions .
TGF-β-induced factor homeobox 2 (TGIF2) belongs to the TALE superfamily of homeodomain proteins that play important roles in many biological programs, including cell proliferation, embryonic development and differentiation. TGIF2 is a context-independent transcriptional regulator. The most extensively studied ability of TGIF2 is the recruitment of HDACs to DNA-bound Smad transcription complexes to induce the suppression of TGF-β signaling . TGIF2 functions in the progression of several cancer types including ovarian, gastric, prostate and colorectal cancers [12,13,14]. TGIF2 was recently reported to promote cervical cancer metastasis by negatively regulating FCMR . Being a target of microRNAs, TGIF2 is involved in various cancer-related processes [16,17,18]. We previously found that TGIF2 phosphorylation induced by EGFR/ERK signaling promoted LUAD stemness since phosphorylated (p)-TGIF2 showed increased stability . However, the role of p-TGIF2 in LUAD metastasis remains largely unexplored.
In this study, we investigated the roles of TGIF2 in the EMT and metastasis of LUAD cells. We found that TGIF2 promoted EMT and metastasis by recruiting HDAC1 to downregulate E-cadherin expression. As a downstream target of EGF/EGFR/ERK signaling, TGIF2 phosphorylation was necessary for recruiting HDAC1 to the EMT program. Dual inhibition of ERK and HDAC1 significantly inhibited TGIF2 enhanced LUAD metastasis. The identification of p-TGIF2 as a key regulator of EMT and metastasis provides a promising target for LUAD therapy.
Human lung cancer cell lines A549 and H1299 were purchased from the American Type Culture Collection (ATCC, Washington, USA) and cultured in RIPM-1640 medium containing 10% fetal bovine serum (FBS), 0.1 mg/mL streptomycin and 100 U/mL penicillin. Cells were maintained at an atmosphere of 5% CO2% and 95% air at 37˚C. All cell lines were recently authenticated by cellular morphology and short tandem repeat profiling.
Cell line establishment
Control or HDAC1-targeting shRNA templates were inserted into the pLV-H1-EF1a-Puro vector (Biosettia, San Diego, CA, USA) (named shCtrl, and shHDAC1). H1299 cells were infected with lentivirus expressing shHDAC1, followed by clone selection using 2 μg/mL puromycin to establish HDAC1 knockdown H1299 cells. TGIF2-silenced and TGIF2-rescue (shTGIF2#2 + TGIF2resis) stable H1299 and A549 cells, TGIF2WT-, TGIF2DD- and TGIF2AA-overexpressing H1299 cells were previously established . The sequences of shRNA-HDAC1was: 5’-GGTGCTGTACATTGACATT-3’.
The western blot steps were described previously . The blots were cut prior to hybridisation with antibodies during blotting. The original images of all blots are presented in the Supplementary Information. The proteins were detected using the following primary antibodies: anti-E-cadherin, HDAC1, Flag, vimentin and fibronectin (Cell Signaling Technology, Danvers, MA, USA). Anti-β-actin, TGIF2, ERK and p-ERK (Santa Cruz Biotechnology, Dallas, TX, USA).
Immunohistochemistry (IHC) staining
The tissue microarrays were purchased from Alenabio Inc. (cat. #LC2081, Shanxi, China). The tissue sections were incubated with primary antibodies against TGIF2, E-cadherin, and Vimentin (1:200) overnight at 4 °C. The tissues were incubated with a peroxidase-conjugated secondary antibody at 37 °C for 1 h before the DAB Substrate Kit was used to reveal bound secondary antibody. The semiquantitative H score was used to estimate the immunoreactivity according to the established protocols described previously .
LUAD cell lines were fixed with 4% paraformaldehyde and were incubated with 5% goat serum for 1 h to block nonspecific interactions. Then cells were labeled with primary antibodies against E-cadherin, Vimentin, TGIF2, HDAC1 or Flag overnight at 4 °C, followed by incubation with fluorescent-dye-labeled secondary antibodies (1:200) (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h. Nuclei were stained with DAPI. Finally, the images were captured with a confocal fluorescence microscope (Olympus, Tokyo, Japan).
Dual-luciferase reporter assay
The CDH1 gene promoter fragment was amplified from human genomic DNA and cloned into the firefly luciferase plasmid pGL3-basic-IRES. H1299 cells were transiently transfected with pGL3-CDH1 reporter plasmid and TGIF2WT or TGIF2AA expression plasmids using Lipofectamine Reagent (Invitrogen, Waltham, MA, USA). After transfection for 36 h, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Luciferase activity was normalized to Renilla luciferase activity. The primer sequences used in this assay are listed in Supplementary table S2.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out using the EZ-Zyme Chromatin Prep Kit (Millipore, Billerica, MA, USA). Anti-TGIF2 antibody and Anti-HDAC1 antibody were used to precipitate DNA crosslinked with TGIF2 and HDAC1, anti-mouse IgG as a negative control. PCR and RT-PCR were performed to detect DNA fragments of the CDH1 promoter region. Primers used in this assay are summarized in Supplementary tables S3,S4.
Cell migration assays
For Transwell assays, 1 × 105 cells were re-suspended in 200 μL of RPMI 1640 medium supplemented with 1% FBS and seeded into 5-μm pore Transwell chamber (Millipore, Burlington, MA, USA). Medium containing 10% FBS was added to the lower chamber. After incubation for 8 h, cells that migrating to the membrane surface were stained with 0.1% crystal violet staining solution. Four random fields were counted per chamber.
For wound healing assays, 1 × 106 A549 or H1299 cells were seeded and grown to 90% confluence. A sterile pipette tip was used to create scratch wounds. Images were taken at 0 h, and 10 h (H1299) or 24 h (A549) with an IX71 inverted microscope (Olympus). Three independent experiments were performed.
Wild type and Flag-TGIF2AA-overexpressing H1299 cell protein lysates were incubated with protein A/G agarose beads (Life Technologies) and antibody overnight at 4 °C. Then, the samples were centrifuged at 2500 rpm for 30 s. The pellets were washed with prechilled phosphate-buffered saline (PBS). Finally, bound proteins were boiled and analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Immunoprecipitates were analyzed by western blotting with anti-TGIF2 antibody (Santa Cruz Biotechnology, Dallas, TX, USA), anti-Flag antibody ((Sigma-Aldrich, St. Louis, MO, USA)) and anti-HDAC1 antibody (Cell Signaling Technology, Danvers, MA, USA).
To confirm whether TGIF2 promotes metastasis in vivo. Six-week-old NOD/SCID male mice were purchased from SPF Biotechnology (Beijing, China). Mice were intravenously injected with 2 × 106 TGIF2-silenced, TGIF2-rescued or control H1299 cells. Twenty days after tumor cell inoculation, the mice underwent bioluminescence imaging and were sacrificed. The lung tissues were fixed with formalin, embedded in paraffin, and subjected to HE staining or IHC staining. The percentage of lung metastatic foci was calculated using the formula: (area of metastatic foci/ total area of five lung lobes) × 100%. The area was measured using Photoshop software (Adobe, San Jose, CA, USA).
To determine whether p-TGIF2 was necessary for TGIF2-enhanced metastasis. 1.5 × 106 H1299-vector, H1299-TGIF2WT or H1299-TGIF2AA cells were subcutaneously injected into each NOD/SCID mouse. Tumor volume was measured using calipers and calculated using the formula: (length × width2)/2. Thirty-five days after inoculation, the mice were sacrificed and subjected to lung metastatic analysis.
For ERK inhibitor and HDAC1 inhibitor treatments, 2 × 106 TGIF2WT-overexpressing H1299 cells were injected into NOD/SCID mice via the tail vein. Twelve days after injection, mice were randomized into four groups (PBS, ERK inhibitor, HDAC1 inhibitor, ERK inhibitor + HDAC1 inhibitor). The mice were intraperitoneally injected with 50 mg/kg ERK inhibitor (SCH772984) (Selleck, Houston, Texas, USA) every day for 14 days. The mice received 80 mg/kg HDAC1 inhibitor (MGCD0103) (Selleck, Houston, Texas, USA) by daily intragastric administration for 14 days, and PBS was used as a control. Thirty days after inoculation, the metastatic foci in the lung were subjected to HE staining or IHC staining.
Gene expression profiles of 532 LUAD patients were downloaded from The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov). Gene set enrichment analysis (GSEA) was performed according to the authors' guidelines published on the Broad Institute web pages (http://www.broadinstitute.org/gsea/index.jsp) with cell adhesion molecules signature and epithelial-mesenchymal transition gene set (from the MSigDB C2 curated gene sets collection) using Signal2Noise ratios. Survival analyses were conducted with the online tool (http://kmplot.com/analysis/index.php?p=service&cancer=lung) using the 2015 version. Patients with lung adenocarcinoma were selected for the First Progression (FP) and Post Progression Survival (PPS) assays. Log-rank was automatically computed.
The data are presented as the mean ± standard deviation. A two-tailed Student’s t-test was performed to compare the differences between the two groups. A one-way ANOVA with post hoc Tukey’s Multiple Comparison Test was used to analyze the xenograft growth. A p-value of < 0.05 was used as the criterion for statistical significance. Spearman’s r test was used to determine the correlation between TGIF2 and E-cadherin. GraphPad Prism 8 was used to perform the statistical analyses.
TGIF2 enhances LUAD cell migration and EMT in vitro
It was reported that cancer stem cell (CSC)-enriched subpopulation exhibits aspects of EMT activation [23, 24]. We previously found that TGIF2 can maintain CSC-like characteristics in LUAD . In this study, gene set enrichment analysis (GSEA) revealed that a lower and higher expression of TGIF2 led to an enrichment of cell adhesion molecules and enrichment of EMT in LUAD patients, respectively (Fig. 1A), suggesting a role for TGIF2 in regulating EMT and metastasis in LUAD. In addition, we analyzed the correlation between the level of TGIF2 and the first progression (FP) and post progression survival (PPS) of patients with lung adenocarcinoma. We found that high TGIF2 expression was associated with poor clinical outcome in patients with LUAD (Fig. S1A and B).
To determine whether TGIF2 plays a role in EMT, several metastasis-related biomarkers were examined in TGIF2-silenced and shRNA-resistant TGIF2-overexpressing H1299 cells (Fig. S2A and B). We observed that Fibronectin, U-Plasminogen Activator (U-PA), Slug, Snail, and Vimentin mRNA levels were positively associated with TGIF2 expression, whereas the E-cadherin mRNA level was negatively associated with TGIF2 expression (Fig. 1B). Silencing of TGIF2 increased the protein level of the key epithelial marker E-cadherin and decreased that of the mesenchymal marker Vimentin and Fibronectin (Fig. 1C and D), which was rescued by the ectopic expression of shRNA-resistant TGIF2 (TGIF2resis, Fig. 1E). We also observed that TGIF2-silenced A549 and H1299 cells showed a decreased capacity for migration (Fig. 1F and G), which was also rescued by ectopically expressed TGIF2 (Fig. S2C and S2D). These results highlight the ability of TGIF2 to promote LUAD cell migration and EMT.
TGIF2 promotes EMT and metastasis of LUAD cells in vivo
To examine the metastasis-promoting effects of TGIF2 in vivo, we established an intravenous mouse xenograft model by injecting H1299-luciferase cells. The silencing of TGIF2 significantly reduced metastasis according to in vivo bioluminescence imaging, which was rescued by the ectopic expression of TGIF2resis (Fig. 2A, B). This result was further confirmed by counting the lung tumor burden (Fig. 2C, D). Furthermore, we observed increased levels of E-cadherin and decreased levels of vimentin in mouse lungs injected with TGIF2-knockdown cells, which was also be rescued by ectopically expressed TGIF2resis (Fig. 2E). These results indicate that TGIF2 contributes to the EMT and metastasis of LUAD cells in vivo.
Phosphorylation of TGIF2 by EGFR/ERK signaling is necessary for TGIF2-enhanced EMT and metastasis in LUAD
We previously demonstrated that the phosphorylation of TGIF2 by EGF/EGFR/ERK signaling promoted the stemness of LUAD cells. To determine whether TGIF2 enhanced LUAD EMT in an EGFR/ERK signaling-dependent manner, H1299 cells were treated with EGF and ERK inhibitor (SCH772984, Fig. 3A). EGF decreased the expression of E-cadherin and increased the expression of vimentin, which was inhibited by ERK inhibition. Furthermore, we observed that the silencing of TGIF2 increased and decreased the EGF-induced expression of E-cadherin and vimentin, respectively (Fig. 3B).
To further investigate the role of TGIF2 downstream of EGFR/ERK signaling, we constructed phosphorylation-deficient TGIF2 mutants (i.e., T182A and T186A, or TGIF2AA for short) that present a loss of phosphorylation at the MAP kinase sites (Fig. 3C). We observed that EGF could no longer induce EMT in TGIF2AA-transfected H1299 cells compared with that in TGIF2WT cells (Fig. 3D). Next, we compared the functions of TGIF2 WT and TGIF2AA in regulating EMT and metastasis. We found that the ectopic expression of TGIF2WT reduced the expression of E-cadherin and enhanced the expression of vimentin, while TGIF2AA had no effect (Fig. 3E, F). The ectopic expression of TGIF2WT changed the cell morphology from epithelial to fibroblastic and spindle-shaped, in stark contrast to control cells, whereas the ectopic expression of TGIF2AA induced a stellate-like phenotype in H1299 cells (Fig. 3G). Compared to the effect of TGIF2WT, TGIF2AA did not increase the migration capacity of H1299 cells (Fig. 3H and S3). In the xenograft mouse model, overexpression of TGIF2AA had no effect on tumor growth compared with that of TGIF2WT (Fig. 3I, J). Consistent with the changes in vitro, TGIF2WT-transfected cells induced more metastatic nodules in the lungs compared with TGIF2AA-overexpressing or empty vector-expressing cells (Fig. 3K). Collectively, these results suggest that the phosphorylation of TGIF2 by EGFR/ERK signaling is necessary to promote EMT and metastasis in LUAD.
p-TGIF2 downregulates the expression of E-cadherin by binding to its promoter
In 60 human non-small cell lung cancer (NSCLC) samples, we found a negative correlation between the expression of TGIF2 and E-cadherin as determined by IHC staining (Fig. 4A, B, C). To explore whether phosphorylation of TGIF2 promoted LUAD EMT by regulating E-cadherin expression, we compared CDH1 (codes for E-cadherin protein) promoter activity following transfection with TGIF2WT or TGIF2AA. TGIF2WT significantly decreased CDH1 promoter activity, while TGIF2AA had no effect (Fig. 4D). We performed a ChIP-qPCR assay to detect TGIF2 binding sites in the human CDH1 gene from − 6 kb to + 3 kb in TGIF2WT-transfected H1299 cells (Fig. 4E). TGIF2 binding sites were found within the − 6 kb to − 4 kb and + 1 kb to + 2 kb regions of the CDH1 promoter (Fig. 4F), which were further confirmed by a ChIP-PCR assay (Fig. 4G). These results demonstrate that the phosphorylation of TGIF2 is necessary for its binding to the CDH1 promoter.
p-TGIF2 recruits HDAC1 to promote LUAD EMT and metastasis
We explored why the phosphorylation of TGIF2 was required for its binding to the CDH1 promoter. Based on previous findings , we examined the involvement of HDACs in the regulation of E-cadherin expression by TGIF2. We searched the Cistrome Data Browser database and found that HDAC1, but not HDAC3, might bind to the − 6 kb to − 4 kb region of the CDH1 promoter, where the TGIF2 binding sites were also shown (Fig. 5A). A ChIP-qPCR assay was performed and showed that HDAC1 bind to the region from − 6 kb to − 4 kb of the CDH1 promoter (Fig. 5B), suggesting that TGIF2 might cooperate with HDAC1 to regulate CDH1 transcription. To further confirm this result, we performed co-immunoprecipitation assays in empty vector- or TGIF2AA- transfected cells (Fig. 5C, D). Endogenous binding of p-TGIF2 with HDAC1 was observed in control cells, but not in phosphorylation-deficient TGIF2 mutants, which was confirmed by immunofluorescence analysis (Fig. 5E). We also observed increased E-cadherin expression after treatment with HDAC1 inhibitor (MGCD0103), but no effect was observed on TGIF2 expression (Fig. 5F). These results indicate that the phosphorylation of TGIF2 is required for HDAC1 recruitment to downregulate E-cadherin expression.
To determine the role of HDAC1 in p-TGIF2-induced EMT and metastasis, we generated a p-TGIF2 mimicking mutant (i.e., T182D and T186D, or TGIF2DD for short, Fig. 5G), which presents a gain-of-function mutation at the MAP kinase sites of TGIF2. We constructed stable H1299 cell lines overexpressing TGIF2DD and silenced HDAC1 in TGIF2DD-overexpressing cells. The ectopic expression of TGIF2DD significantly decreased and increased the expression of E-cadherin and vimentin, respectively, which was rescued by HDAC1 knockdown (Fig. 5H, I). Moreover, the increased migration capacity of p-TGIF2-expressing H1299 cells were also repressed by HDAC1 knockdown (Fig. 5J, K). These results indicate that the phosphorylation of TGIF2 recruits HDAC1 to repress the transcription of E-cadherin, which promotes EMT and metastasis in LUAD.
TGIF2-enhanced LUAD metastasis is inhibited by dual inhibition of ERK and HDAC1
To explore whether the inhibition of p-TGIF2 and HDAC1 can repress the exacerbated metastasis of TGIF2-overexpressing (TGIF2high) cells, we constructed an intravenous mouse xenograft model using TGIF2-overexpressing H1299 cells; PBS, ERK inhibitor (SCH772984), HDAC1 inhibitor (MGCD0103), or ERK inhibitor plus HDAC1 inhibitor were administrated to different groups of mice (Fig. 6A). We observed decreased tumor metastasis with either administration of ERK or HDAC1 inhibitor. Importantly, dual inhibition of ERK and HDAC1 significantly ameliorated TGIF2high cell-induced metastasis (Fig. 6B), which was confirmed based on the tumor burden with H&E staining (Fig. 6C, D). In addition, we observed increased expression of E-cadherin in mouse lungs treated with ERK inhibitor or HDAC1 inhibitor, which was further enhanced by dual inhibition of ERK and HDAC1 (Fig. 6E). These results suggest that the dual inhibition of p-TGIF2 and HDAC1 can effectively repress metastasis in TGIF2-overexpressing LUAD cells, and thus may be a promising therapeutic strategy.
In the present study, we demonstrated that TGIF2 played a key role in regulating EMT and metastasis in LUAD. Phosphorylation of TGIF2 by EGFR/ERK signaling recruited HDAC1 and repressed E-cadherin transcription, resulting in EMT and metastasis. Accordingly, the dual inhibition of TGIF2 phosphorylation and HDAC1 repressed TGIF2-enhanced EMT and metastasis (Fig. 6F).
TGIF2 was previously shown to recruit HDACs to repress the activation of TGF-β-responsive transcription . However, few studies have investigated the mechanism by which TGIF2 is involved in cancer progression. In this study, we revealed that TGIF2 recruits HDAC1 to repress E-cadherin transcription and found that the ectopic expression of TGIF2WT promoted LUAD cell migration, EMT, and metastasis, while the phosphorylation-deficient TGIF2 mutant lost these functions; therefore, TGIF2 phosphorylation as a consequence of EGFR/RAS/ERK signaling was necessary for recruiting HDAC1 and activating the EMT program. Moreover, we observed endogenous binding of p-TGIF2 with HDAC1 in LUAD cells, but not in phosphorylation-deficient TGIF2 mutant cells. Our findings indicated that the phosphorylation of TGIF2 is a key step for HDAC1 recruitment in TGIF2-promoted EMT and metastasis in LUAD.
TGIF2 has been reported to interact with PKM2 and recruit HDAC3 to the E-cadherin promoter, promoting EMT in colon cancer . This indicates that TGIF2 could recruit different HDACs to repress E-cadherin expression in different cancer types, reflecting tumor heterogeneity. We previously demonstrated that TGIF2 phosphorylation promoted OCT4 transcription in an HDAC-independent manner, because TGIF2 phosphorylation improved its stability. Furthermore, TGIF2 may exert its transcription function by cooperating with other cofactors in LUAD, which is consistent with the context-dependent activities of other TALE homeoproteins .
The MAPK pathway, commonly known as the RAS/RAF/MEK/ERK signal cascade, is the most frequently mutated signaling pathway in lung cancer; targeting the MAPK pathway has long been considered a promising strategy in cancer therapy . However, the clinical benefits of related inhibitors are compromised by the frequent occurrence of acquired resistance. HDAC inhibition has been reported to enhance the antitumor activity of MEK inhibitors in lung cancers harboring RAS mutations . Another study emphasized the active inhibitory role of HDAC and ERK signaling cascades in restricting MHC II expression in lung cancer cells, and suggested that the combinatorial blockade of these pathways may engender new responses to checkpoint therapies . The present study showed that the expression of E-cadherin in LUAD was actively restricted by EGFR/ERK/TGIF2 signaling and HDAC1 expression, and dual inhibition of ERK and HDAC1 showed a greater inhibitory effect on TGIF2-induced LUAD metastasis than either treatment alone. Because of its link to immunotherapy resistance, the targeting of EMT may inhibit cancer immune suppression . Based on our and previous findings, the inhibition of EMT by targeting p-TGIF2 could also improve the outcomes in cancer immunotherapy, though this requires further validation.
In this study, we demonstrated that the phosphorylation of TGIF2 by EGFR/ERK signaling promoted EMT and metastasis in LUAD by recruiting HDAC1 to downregulate E-cadherin expression. Combined ERK and HDAC1 inhibition significantly repressed TGIF2-enhanced metastasis, suggesting that TGIF2-overexpressing LUAD patients could potentially be treated by p-TGIF2 and HDAC1 inhibitions.
TGF-β-induced factor homeobox 2
Gene set enrichment analysis
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 [J]. CA Cancer J Clin. 2021;71(1):7–33.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin. 2016;66(2):115–32.
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances [J]. Translational lung cancer research. 2016;5(3):288–300.
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments [J]. Lancet. 2017;389(10066):299–311.
Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells [J]. J Clin Investig. 2009;119(6):1417–9.
Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease [J]. Cell. 2009;139(5):871–90.
Taki M, Abiko K, Ukita M, et al. Tumor immune microenvironment during epithelial-mesenchymal transition [J]. Clin Cancer Res. 2021;27(17):4669–79.
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression [J]. Nat Rev Cancer. 2013;13(2):97–110.
Padmanaban V, Krol I, SuhaiL Y, et al. E-cadherin is required for metastasis in multiple models of breast cancer [J]. Nature. 2019;573(7774):439–44.
Lu Z, Ghosh S, Wang Z, et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion [J]. Cancer Cell. 2003;4(6):499–515.
Melhuish TA, Gallo CM, Wotton D. TGIF2 interacts with histone deacetylase 1 and represses transcription [J]. J Biol Chem. 2001;276(34):32109–14.
Imoto I, Pimkhaokham A, Watanabe T, et al. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines [J]. Biochem Biophys Res Commun. 2000;276(1):264–70.
Lips EH, van Eijk R, de Graaf EJ, et al. Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis [J]. BMC Cancer. 2008;8:314.
Chen H, Zhu XM, Luo ZL, et al. Sevoflurane induction alleviates the progression of gastric cancer by upregulating the miR-34a/TGIF2 axis [J]. Eur Rev Med Pharmacol Sci. 2020;24(22):11883–90.
Jiang J, Wu RH, Zhou HL, et al. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR [J]. Eur Rev Med Pharmacol Sci. 2020;24(11):5953–62.
Diao Y, Jin B, Huang L, et al. MiR-129-5p inhibits glioma cell progression in vitro and in vivo by targeting TGIF2 [J]. J Cell Mol Med. 2018;22(4):2357–67.
Hu Y, Pu Q, Cui B, et al. MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting Tgif2 [J]. Int J Clin Exp Pathol. 2015;8(8):8921–8.
Krzeszinski JY, Wei W, Huynh H, et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2 [J]. Nature. 2014;512(7515):431–5.
Du R, Shen W, Liu Y, et al. TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness [J]. Signal Transduct Target Ther. 2019;4:60.
Gao W, Wen H, Liang L, et al. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer [J]. Theranostics. 2021;11(6):2564–80.
Shen W, Zhang X, Du R, et al. Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner [J]. Br J Cancer. 2020;123(5):730–41.
Shen W, Du R, Li J, et al. TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways [J]. Signal Transduct Target Ther. 2016;1:16013.
Pang R, Law WL, Chu AC, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer [J]. Cell Stem Cell. 2010;6(6):603–15.
Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells [J]. Can Res. 2012;72(7):1878–89.
Hamabe A, Konno M, Tanuma N, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition [J]. Proc Natl Acad Sci USA. 2014;111(43):15526–31.
Dard A, Reboulet J, Jia Y, et al. Human HOX proteins use diverse and context-dependent motifs to interact with TALE class cofactors [J]. Cell Rep. 2018;22(11):3058–71.
Liu F, Yang X, Geng M, et al. Targeting ERK, an Achilles’ heel of the MAPK pathway, in cancer therapy [J]. Acta Pharm Sin B. 2018;8(4):552–62.
Yamada T, Amann JM, Tanimoto A, et al. Histone deacetylase inhibition enhances the antitumor activity of a mek inhibitor in lung cancer cells harboring RAS mutations [J]. Mol Cancer Ther. 2018;17(1):17–25.
Neuwelt AJ, Kimball AK, Johnson AM, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms [J]. J Immunother Cancer. 2020;8(1):e000441.
Guo Y, Lu X, Chen Y, et al. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells [J]. Sci Adv. 2021;7(21):eabd7455.
We thank Prof. Jianying Zhang for suggestions in study design and revision of the paper.
This work was supported by the Key Scientific and Technological Project of Henan Province (No. 222102310144 to Renle Du); National Natural Science Foundation of China (No. 82203287 to Renle Du); National Natural Science Foundation of China (No. 81802466 to Wenzhi Shen); Project funded by China Postdoctoral Science Foundation (No. 2022M722874 to Renle Du).
Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Zhengzhou University. The animal experiments of this study were approved by the Institutional Animal Care and Use Committee of the Zhengzhou University (Ethic approved number: 2019003). The animal experiments were conducted in accordance with the ARRIVE guidelines.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Du, R., Wang, C., Liu, J. et al. Phosphorylation of TGIF2 represents a therapeutic target that drives EMT and metastasis of lung adenocarcinoma. BMC Cancer 23, 52 (2023). https://doi.org/10.1186/s12885-023-10535-9